Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIDE-Lung02: Rilvegostomig vs Pembrolizumab in 1L Squamous mNSCLC
NCT06692738Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2024
- Primary completion
- Jul 2030
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial of rilvegostomig in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Overall Survival and Progression-Free Survival. Started Nov 2024; status: recruiting.
02
Drugs
rilvegostomig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06692738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06692738.